This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Smith & Nephew Expands Uterine Care Portfolio With Innovative Diagnostic Device

LONDON, Oct. 15, 2013 /PRNewswire/ -- Smith & Nephew (LSE:SN NYSE:SNN), the global medical technology business, today announces an agreement with Femasys Inc., the medical device developer of women's healthcare solutions, to become the sole provider in the United States of Femasys' FemVue ® Saline-Air Device. FemVue is a non-radiologic device that aids in the evaluation of a woman's fallopian tubes as part of a sono-hysterosalpingogram (Sono HSG) procedure – an important test that can help assess a woman's ability to become pregnant.

The agreement was announced yesterday at the conjoint meeting of the International Federation of Fertility Societies (IFFS) and the American Society of Reproductive Medicine (ASRM) in Boston.

"We are pleased to offer gynecologists and their patients this innovative and minimally-invasive diagnostic test," says Mira Sahney, Vice President and General Manager of Smith & Nephew's Gynecology business. "FemVue complements our TRUCLEARâ„¢ System and reinforces our commitment to offer industry-leading innovation that benefits healthcare providers and the patients they serve."

The FemVue device allows physicians to expand their office-based services with a procedure that is more convenient for patients and cost-effective for payors. Rather than performing a more expensive hysterosalpingogram (HSG) procedure in a hospital or outpatient radiology center setting, physicians are able to eliminate the use of x-rays by coupling saline and air with existing ultrasound technology when performing the Sono-HSG procedure. This procedure can be performed quickly and conveniently in the outpatient setting of a gynecologist's office or fertility clinic. Results are generally available during the same office visit.

"FemVue can be easily incorporated into any gynecological practice, allowing women to benefit from this much needed technology," says Kathy Lee-Sepsick, President & CEO of Femasys Inc.  "We are excited to begin this partnership with Smith & Nephew and are confident FemVue's reach will be greatly expanded."

"There is anxiety and stress inherent in the fertility treatment process; FemVue helps ease some of that natural discomfort," says Dr. Chuck Miller of the Advanced IVF Institute in Chicago.  "My patients are more comfortable and the procedure is more efficient in the known environment of our office, rather than having to perform an HSG in the hospital."

FemVue complements the TRUCLEAR System, which is the cornerstone of Smith & Nephew's uterine care business. As part of the diagnostic procedure during which FemVue is used, both the uterus and fallopian tubes are evaluated for abnormalities. If uterine polyps or fibroids are suspected, the patient could be a candidate for a follow-up TRUCLEAR procedure, during which the polyps or fibroids would be removed.  Similar to tubal factors, polyps and fibroids are also a known cause of infertility.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

DOW 18,165.39 +123.85 0.69%
S&P 500 2,121.96 +17.76 0.84%
NASDAQ 5,097.62 +64.8690 1.29%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs